Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21663307 | 0.83 | KDM4E (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL21663311 | 0.81 | KDM4E (0.34) | KDM4EMEN1KMT2A | |
| SCHEMBL21663142 | 0.78 | KDM4E (0.32) | KDM4EMEN1KMT2A | |
| SCHEMBL21663300 | 0.78 | ADORA2A (0.38) | KDM4EMEN1KMT2ACREBBP | |
| SCHEMBL21663151 | 0.70 | CYP1A2 (0.36) | KDM4EMEN1KMT2ABRD4BRD2 | |
| SCHEMBL24329220 | 0.69 | SMARCA4 (0.32) | — | |
| SCHEMBL21663175 | 0.69 | BRD4 (0.32) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL21662993 | 0.67 | PDE5A (0.34) | KDM4EMEN1KMT2A | |
| SCHEMBL21663204 | 0.65 | CYP1A2 (0.38) | KDM4EMEN1KMT2A | |
| SCHEMBL21663156 | 0.64 | KDM4E (0.33) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20210214358-A1 | CDK4/6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF AND USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3786161-A1 | CDK4/6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF AND USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | CYP2D6, PNPO, CYP2B6 | KDM4E 3449/4885MEN1 728/4885KMT2A 2962/4885 |
| US-20210214358-A1 | CDK4/6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF AND USE THEREOF | CDK4, CDK6, CDK2 | KDM4E 680/4885MEN1 2967/4885KMT2A 527/4885 |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CYP2D6, PNPO, CYP2B6 | KDM4E 3449/4885MEN1 728/4885KMT2A 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.